Showing results (991-1000 of 1,073) with videos related to
Sort By:
Pageof 108
Bioorganic & Medicinal Chemistry Letters|December 28, 2007
Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitorsIsabelle Paquin, Stéphane Raeppel, Silvana Leit, et al.Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.Immunity|October 23, 2021
Nitric oxide controls proliferation of Leishmania major by inhibiting the recruitment of permissive host cellsPauline Formaglio, Mohamad Alabdullah, Anastasios Siokis, et al.Nature Immunology|May 22, 2023
Spatial dysregulation of T follicular helper cells impairs vaccine responses in agingAlyssa Silva-Cayetano, Sigrid Fra-Bido, Philippe A Robert, et al.Journal for Immunotherapy of Cancer|April 7, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancerAlexey Revenko, Larissa S Carnevalli, Charles Sinclair, et al.Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.Journal of Synchrotron Radiation|May 2, 2015
Demonstration of simultaneous experiments using thin crystal multiplexing at the Linac Coherent Light SourceY Feng, R Alonso-Mori, T R M Barends, et al.Annals of Intensive Care|May 26, 2020
Use, timing and factors associated with tracheal intubation in septic shock: a prospective multicentric observational studyC Darreau, F Martino, M Saint-Martin, et al.Leukemia|February 24, 2001
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative GroupE Vilmer, S Suciu, A Ferster, et al.Blood|June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activityAntonio Sacco, Cinzia Federico, Katia Todoerti, et al.Pageof 108